Madhavan Balachandran Purchases Shares in Stevanato Group S.p.A.

Madhavan Balachandran, an insider, bought 4,975 shares of Stevanato Group S.p.A. (NYSE:STVN) on June 12, 2026. The stock traded near $18.39 on Friday, reflecting the company's market position in the healthcare sector.

Insider Buying and Selling at Stevanato Group S.p.A.

Madhavan Balachandran wasn't the only insider active recently. On June 12, Marco Dal Lago, the Chief Financial Officer, also bought 2,356 shares. Meanwhile, on June 15, several insiders, including Karen Flynn and Donald Morel Jr., sold 1,493 shares each at an average price of $17.09.

Other Institutional Activity in Stevanato Group S.p.A.

Several institutional investors have been adjusting their positions in Stevanato Group S.p.A. Conestoga Capital Advisors, LLC increased its holdings by 602,050 shares, bringing its total to 8,491,751 shares valued at approximately $116.76 million, a 7.6% increase. On the other hand, Neuberger Berman Group LLC decreased its position by 312,219 shares, ending with 4,475,492 shares worth about $61.54 million, a 6.5% reduction. TimesSquare Capital Management, LLC slightly trimmed its stake by 10,605 shares, holding 3,489,716 shares valued at $47.98 million. T. Rowe Price Investment Management, Inc. reduced its holdings significantly by 698,724 shares, now holding 3,224,908 shares valued at around $44.34 million, marking a 17.8% decrease.

Stevanato Group S.p.A. Stock Down 12.6%

Shares of Stevanato Group S.p.A. traded around $18.39 on Friday. The company, with a market cap of approximately $5.02 billion, holds a P/E ratio of 31.7 and a forward P/E of 21.9, indicating investor expectations for growth. The stock's beta is 0.776, suggesting lower volatility compared to the broader market. Over the past year, it has ranged from $12.89 to $28.00. The 50-day moving average is $17.39, while the 200-day moving average is $19.57.

Recent Earnings

In its recent earnings report, Stevanato Group S.p.A. posted revenue of $1.20 billion, reflecting a 6.6% growth. The company's net margin stood at 11.7%, with a return on equity of 9.6%. Earnings per share were reported at $0.58. The next earnings announcement is expected on May 7, 2026.

Dividend

Stevanato Group S.p.A. pays an annual dividend of $0.06 per share, yielding 0.34%, with a payout ratio of about 10.6%.

Analysts Set New Price Targets

On June 16, 2026, TD Cowen initiated coverage on Stevanato Group S.p.A. with a 'buy' rating and a price target of $25. Wolfe Research assumed a 'buy' rating on June 2, 2026, with a target of $21. The consensus among analysts is a 'buy' rating, with an average target price of $24.45 based on 10 opinions.

About Stevanato Group S.p.A.

Stevanato Group S.p.A., headquartered in Piombino Dese, Italy, designs and manufactures products for the biopharma and healthcare industries. It operates through two main segments: Biopharmaceutical and Diagnostic Solutions, and Engineering. The company offers a wide range of products, including syringes, vials, and drug delivery systems, and provides services like contract development and manufacturing. Founded in 1949, it employs around 6,010 people.

Bottom Line

Madhavan Balachandran's recent purchase of Stevanato Group S.p.A. shares adds to the insider activity in the company. With a solid market presence and recent analyst endorsements, Stevanato Group S.p.A. remains a company to watch in the healthcare sector. Remember, insider transactions are reported after the fact and may not indicate current positions.